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The first successful transcatheter aortic valve implant (TAVI) in 
2002[1] signalled the start of an era in which the definitive treatment 
of patients with aortic stenosis and a prohibitively high surgical 
risk became a reality. This exciting treatment modality has evolved 
from a salvage procedure in the extreme-risk patient to being 
investigated for patients at intermediate and even low surgical risk.[2-5] 
Despite the publication of local experience with TAVI over the past 
7  years, demonstrating results comparable to those reported in the 
pivotal international PARTNER A trial in high-risk patients,[5] rapid 
expansion of the procedure as seen elsewhere has not been evident 
in South Africa (SA). An important obstacle is reluctance of many 
health funders to accept it as a valid alternative for the intermediate- 
or high-risk patient. A recent report shows success rates >90%, with 
low rates of adverse outcomes (stroke, vascular complications) and a 
1-year survival rate of 81% with sustained improvement in clinical, 
functional and echocardiographic parameters.[6]
A major challenge in applying this new technology lies in the 
prediction of which patient is most likely to benefit. Over the 
decade and a half since the first TAVI, various attempts have been 
made to develop risk prediction models (Table 1). The predictive 
ability of most of these models was relatively disappointing, with 
inadequately powered area under the curve (AUC) values ranging from 
0.6 to 0.65. These risk prediction scores (the logistic EuroSCORE,[7] 
EuroSCORE II[8] and Society of Thoracic Surgeons (STS) predicted risk 
of mortality[9]) are used routinely as there are few alternatives.
An important factor influencing the local validity of existing 
prediction models is the heterogeneity of the elderly populations and 
medical landscapes in TAVI registries globally. Significant differences 
exist between numerous indicators of health in developed countries 
and SA, including socioeconomic status, access to medical care, level 
of education and health-seeking behaviour. For example, there may 
be a big difference between an 85-year-old living independently in 
SA and one in the UK, or an 80-year-old who drives a car in SA and 
an age-matched counterpart in Japan. Further to that, in terms of 
the medical landscape, healthcare funding and access to specialised 
investigations and functional assessments are less readily available 
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Background. Transcatheter aortic valve implantation (TAVI) has undergone rapid expansion internationally over the past 15 years. In view 
of resource constraints in developing countries, a major challenge in applying this technology lies in identifying patients most likely to 
benefit. The development of a risk prediction model for TAVI has proved elusive, with a reported area under the curve (AUC) of 0.6 - 0.65. 
The available models were developed in a First-World setting and may not be applicable to South Africa (SA).
Objectives. To evaluate novel indicators and to develop a TAVI risk prediction model unique to the SA context. The current work represents 
the important initial steps of derivation cohort risk model development and internal validation.
Methods. Seven-year experience with 244 successive TAVI implants in three centres in Western Cape Province, SA, was used to derive risk 
parameters. All outcomes are reported in accordance with the Valve Academic Research Consortium definitions. Multiple preprocedural 
variables were assessed for their impact on 1-year survival using univariate and multivariate models.
Results. Factors found not to correlate with 1-year survival included age, renal function and aortic valve gradients. The commonly used 
surgical risk prediction models (Society of Thoracic Surgeons score and EuroSCORE) showed no correlation with outcomes. Factors 
found to correlate best with 1-year survival on multivariate analysis were preprocedural body mass index (BMI) (favouring higher BMI), 
preprocedural left ventricular end-diastolic dimension (LVED) and ejection fraction (EF) (favouring smaller LVED and higher EF), 
absence of atrial fibrillation, and three novel parameters: independent living, ability to drive a car, and independent food acquisition/
cooking. Discriminant analysis of these factors yielded an AUC of 0.8 (95% confidence interval 0.7 - 0.9) to predict 1-year survival, with 
resubstitution sensitivities and specificities of 72% and 71%, respectively.
Conclusions. Apart from existing predictors, we identified three novel risk predictors (independent living, ability to drive a car, and 
independent food acquisition/cooking) for 1-year survival in TAVI candidates. These novel parameters performed well in this early 
evaluation, with an AUC for predicting 1-year survival higher than the AUCs for many of the internationally derived parameters. The 
parameters are inexpensive and easy to obtain at the initial patient visit. If validated prospectively in external cohorts, they may be applicable 
to other resource-constrained environments.
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here compared with countries where many of the existing models 
were developed.
Objectives
We postulate that unique prediction parameters exist for the SA 
TAVI community, stemming from the local patient profile as well 
as from the SA healthcare system. We used the data from a 7-year 
experience with TAVI in a private-public partnership initiative to 
develop the initial phases of a risk prediction model specific to the 
SA TAVI patient cohort. The ultimate goal is to develop a validated 
and operational risk prediction model. In this article we address the 
important initial steps of derivation cohort model development and 
internal validation.
The process of developing a risk prediction model includes 
multivariate analyses of factors thought to predict outcome, followed 
by an internal validation process. Once a model has been established 
from the derivation cohort, it is subjected to external validation 
processes using larger patient cohorts. The model can then undergo 
updating and revisions. Finally, the model has to be subjected 
to impact studies to assess influence on behaviour and (self-) 
management of doctors and individuals, and subsequently on health 
outcomes and cost-effectiveness, before being fully operational.[10]
Methods
The research was approved by the Health Research and Ethics 
Committee of Stellenbosch University on 23 June 2016 (ref. no. 
N16/01/005). All processes were conducted in accordance with the 
Declaration of Helsinki. No patient interaction was sought during the 
course of the research, as we retrospectively reported from a registry 
that was kept during the course of good clinical practice. All patient 
data were anonymised and aggregated at the point of data entry.
The data used to develop this derivation cohort risk prediction 
model came from 7-year experience (October 2009 - September 
2016) with 244 consecutive TAVI procedures at two hospitals 
(Panorama Mediclinic and Vergelegen Mediclinic) in Western Cape 
Province, SA. From November 2014 onwards, the patients’ data 
were also entered into a parallel national registry (SHARE-TAVI 
registry), which was not used for the current report. A multiplicity of 
preprocedural parameters as well as 1-year outcomes were collected 
prospectively as part of routine practice and clinical audit. All 
definitions are reported in accordance with the Valve Academic 
Research Consortium recommendation, which reflects validated and 
comparable measures of outcome and clinical efficacy.[11]
The independent variables that were assessed for their associations 
with 1-year survival included a wide array of clinical, standard 
anthropometric, echocardiographic and biochemical data. Impor-
tantly, because of limited formal support structures in SA, we 
included a number of unique parameters listed under ‘Measurements 
of functional and social independence’ (see Table 2 for independent 
variables assessed with definitions). The composite endpoint/
dependent variable was 1-year all-cause mortality/survival rates.
Statistical analysis
For univariate analysis of possible predictors of 1-year survival, 
receiver operating characteristic (ROC) curve analyses were used 
for continuous predictors, and cross-tabulation with the χ2 test for 
categorical predictors. Factors predictive of 1-year outcomes using 
univariate analysis were used in multivariate analysis. Multivariate 
models were fitted using logistic regression to report odds ratios 
(ORs), and discriminant analysis to get an indication of prediction 
accuracy. For the latter, leave-one-out cross-validation was used as 
a measure of prediction accuracy (sensitivity and specificity). In 
the abovementioned measure, cases are omitted one by one, and 
prediction models (excluding the selected case) are used to predict 
the selected case.
Results
The patient profile and outcomes of this cohort have been reported 
previously.[6] In brief, all participants were assessed by the heart 
valve team and found to have a prohibitively high risk for surgical 
valve replacement. The baseline characteristics demonstrated a 
male preponderance (56%) and a mean age of 80 years. The average 
EuroSCORE and STS score was 26.5% and 7.89%, respectively, 
which is comparable to previous flagship TAVI trials.[2] Of the 
244 patients who received TAVI during this period, 75% received 
the Edwards SAPIEN valve and the remaining 25% received the 
Medtronic CoreValve. The preferred vascular access route was the 
transfemoral (73%), followed by transapical (17%) and transaortic 
(10%). The baseline comorbidity rates are shown in Table 3. For the 
current analysis, 1-year outcome data were available for 95% of the 
244 participants.
Univariate results
Continuous variables. Table 4 shows univariate associations that 
continuous variables had with 1-year survival. The direction of effect 
was such that higher body mass index (BMI), smaller left ventricular 
Table 1. Existing risk prediction models
Database/registry/scoring system Outcome Area under curve*
SOURCE TAVI registry[8] 1-year mortality 0.6576 (TA), 0.7062 (TF)
SOURCE TAVI registry[8] 30-day survival 0.609 (TA), 0.635 (TF)
EuroSCORE II[16] 30-day mortality 0.54
STS score[9] 30-day mortality 0.57
OBSERVANT score[17] 30-day mortality 0.71
STS/ACC TVT-TAVR score[18] 30-day mortality 0.68
FRANCE 2 cohort[13] 30-day mortality 0.59
PARTNER[6] 6-month mortality or poor outcome 0.64
TARIS[19] 1-year mortality 0.60
Essential Frailty Toolkit[15] 1-year mortality 0.78
SOURCE = SAPIEN Aortic Bioprosthesis European Outcome; TAVI = transcatheter aortic valve implant; TF = transfemoral; TA = transapical; STS = Society of Thoracic Surgeons;  
ACC = American College of Cardiology; TVT = transcatheter valve therapy; TAVR = transcatheter aortic valve replacement.
*In validation cohorts when reported.
493       June 2020, Vol. 110, No. 6
RESEARCH
Table 2. Independent variables assessed for effect on 1-year survival
Demographic information
Age
Gender
Recognised scoring systems
STS score
Log EuroSCORE
Past medical history
Prior valve surgery
Prior coronary artery bypass grafting
Prior cerebrovascular accidents
Body mass index
Chronic respiratory symptoms
Peripheral vascular disease
Renal function
Pacemaker
Electrocardiographic parameters
Including but not limited to rhythm disturbances (AF)
Symptomatic unrevascularised coronary artery disease
Echocardiographic parameters
Left ventricular ejection fraction
Left ventricular end-diastolic dimension
Preprocedural mitral regurgitation
Aortic valve area
Aortic valve gradients
Existing functional scales
NYHA dyspnoea scale
Canadian Classification of Angina scale
Measurements of functional and social independence Definition
Lives alone  Candidate is deemed to live alone if he or she stays alone or with 
spouse in a house or apartment, including a retirement facility, but 
not in a care facility or old-age home
Drives a car Candidate can still drive a car
Method of food acquisition  Candidate is deemed to ‘self-cook’ if he or she is responsible for the 
preparation of the majority of meals, or if the meals are prepared by 
the candidate’s spouse
Assistive devices  Candidate is deemed to be independent of assistive devices if he or 
she uses no more than a cane/walking stick for mobilisation, both in 
and outside the house 
STS = Society of Thoracic Surgeons; AF = atrial fibrillation; NYHA = New York Heart Association.
Table 3. Baseline characteristics of the cohort (N=244)[6] (reproduced with permission)
Previous coronary artery bypass graft surgery, n (%) 95 (38.8)
Previous surgical aortic valve replacement, n (%) 5 (2.0)
Preprocedural pacemaker, n (%) 41 (16.8)
Documented frailty, n (%) 10 (4.1)
Preprocedural major organ system dysfunction, n (%) 121 (49.5)
Underlying/previously diagnosed malignancy (active/current), n (%) 24 (9.8)
Class 3 obesity (BMI >35 kg/m2), n (%) 244 (10.2)
Porcelain aorta, n (%) 22 (9.0)
Previous stroke or peripheral vascular disease, n (%) 34 (13.9)
Preprocedural atrial fibrillation, n (%) 37 (15.2)
Creatinine (µmol/L), median (SD) 114 (75)
Ejection fraction (%), median (SD) 53 (13)
BMI = body mass index; SD = standard deviation.
494       June 2020, Vol. 110, No. 6
RESEARCH
end-diastolic diameter (LVED), higher ejection fraction (EF) and 
smaller aortic valve area (AVA) were associated with better 1-year 
survival. Notably, the majority of the factors, including age and renal 
function, were not associated with 1-year survival. There was no 
demonstrable association between the EuroSCORE and STS score 
and outcomes.
Categorical variables. Table 5 shows univariate associations 
that categorical variables had with 1-year survival. The level of the 
effect was such that 1-year survival was favoured by BMI >35 kg/m2, 
absence of atrial fibrillation, independent living, ability to drive a car, 
and self-acquisition (or via spouse) of most meals (see definitions).
Multivariate results
The factors identified as correlating with outcome on the univariate 
analysis were used in multivariate testing. Table 6 shows respective 
p-values and ORs for predicting 1-year survival in a multivariate 
logistic regression model. Using discriminant analysis of predictors in 
Table 6 yielded an AUC of 0.8 (95% confidence interval (CI) 0.7 - 0.9) 
Table 4. Univariate receiver operator curve analysis of continuous variables associations with 1-year mortality/survival
Continuous variable AUC (95% CI) AUC p-value
Age 0.51 (0.4 - 0.63) 0.40
EuroSCORE 0.57 (0.43 - 0.7) 0.13
STS score 0.60 (0.45 - 0.76) 0.08
Preprocedural creatinine 0.47 (0.34 - 0.61) 0.67
Preprocedural BMI 0.67 (0.54 - 0.8) 0.01
Preprocedural PR interval 0.53 (0.39 - 0.68) 0.34
Preprocedural QRS duration 0.56 (0.44 - 0.68) 0.18
Preprocedural LVEDD 0.63 (0.51 - 0.76) 0.01
Preprocedural LVESD 0.62 (0.49 - 0.74) 0.03
Preprocedural EF 0.63 (0.52 - 0.74) 0.01
Preprocedural IVS 0.54 (0.43 - 0.65) 0.23
Preprocedural LVPW 0.56 (0.45 - 0.66) 0.17
Preprocedural AVA 0.64 (0.53 - 0.75) 0.01
Preprocedural AV gradient 0.53 (0.41 - 0.65) 0.32
Aortic annulus dimension 0.56 (0.43 - 0.69) 0.16
Preprocedural NYHA dyspnoea scale 0.56 (0.47 - 0.66) 0.09
Preprocedural CCS angina score 0.50 (0.31 - 0.68) 0.51
Preprocedural AR 0.49 (0.4 - 0.59) 0.57
Preprocedural MR 0.57 (0.47 - 0.68) 0.08
AUC = area under the curve; CI = confidence interval; STS = Society of Thoracic Surgeons; BMI = body mass index; LVEDD = left ventricular end-diastolic diameter;  
LVESD = left ventricular end-systolic diameter; EF = ejection fraction; IVS = intraventricular septum; LVPW = left ventricular posterior wall; AVA = aortic valve area;  
AV = aortic valve; NYHA = New York Heart Association; CCS = Canadian Cardiovascular Society; AR = aortic regurgitation; MR = mitral regurgitation.
Table 5. Univariate cross-tabulation analysis of categorical variables associations with 1-year mortality/survival
Categorical variable p-value (χ2) 1-year survival rate
Valve type used 0.22 Edwards SAPIEN 83%, CoreValve 74%
Sex 0.90 Males 81%, females 82%
Previous CABG 0.57 No CABG 81%, previous CABG 84%
Previous valve surgery 0.91 Previous valve surgery 83%, no previous valve surgery 82%
Permanent pacemaker 0.72 Pacemaker 80%, no pacemaker 82%
Documented frailty 0.91 Frailty 81%, no frailty 82%
Major organ system failure 0.84 Major organ system failure 81%, no major organ failure 82%
Underlying malignancy 0.31 Malignancy 89%, no malignancy 80%
BMI 0.006 BMI >35 kg/m2 100%, BMI <35 kg/m2 80%
Porcelain aorta 0.69 Porcelain aorta 78%, no porcelain aorta 82%
Severe COPD 0.21 No severe COPD 80%, severe COPD 88%
PVD/previous stroke 0.31 No PVD/previous stroke 83%, previous stroke 74%
Preprocedural AF 0.003 No AF 85%, AF 61%
Independent living 0.054* Lives alone/with spouse 85%, lives in care facility/old-age home 69%
Walks with aid 0.16 Independent walking (including use of simple walking stick) 85%, 
requires more aid than walking stick for mobilisation 74%
Drives a car 0.009 Can drive a car 89%, cannot drive a car 71%
Food acquisition 0.005 Self-cooks 89%, someone else cooks (excluding spouse, i.e. external 
help) 65%
CABG = coronary artery bypass graft; BMI = body mass index; COPD = chronic obstructive pulmonary disease; PVD = peripheral vascular disease; AF = atrial fibrillation.
*Trend towards statistical significance and therefore included in the proposed risk prediction model.
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to predict 1-year survival, with resubstitution sensitivities and specifici-
ties of 72% and 71%, respectively (Fig. 1). Leave-one-out cross-valida-
tion yielded sensitivities and specificities for predicting 1-year survival 
of 63% and 67%, respectively.
Optimising the risk prediction model’s sensitivity for detecting 
1-year survival to a maximum of 85% yielded lower specificity for 
detecting 1-year survival of only 35%. Conversely, the model can 
be optimised to a maximum specificity of 88%, with a sensitivity 
of 58%.
Discussion
The factors identified as predictors of outcome and hence proposed 
components of a risk prediction model (subject to external validation) 
were derived from the largest SA TAVI outcome report.[6] The rationale 
for evaluating these locally derived factors was to address the lack of 
satisfactory prediction models as well as the global heterogeneity in 
the health of the elderly as well as in healthcare systems. Our results 
can be summarised as the identification of seven parameters, three 
of which are novel, yielding promising predictive abilities for 1-year 
survival. Importantly in the context of local constraints, all the 
parameters identified are easily obtained during the interview with 
the patient and with a good-quality transthoracic echocardiogram, 
and do not involve complex, laborious and expensive functional, 
biochemical and psychometric testing. The novel components of 
the model are not operator dependent. Our study adds to the 
growing body of evidence that functional parameters of self-care and 
independence in activities of daily living are of principal importance 
in predicting success or futility post TAVI.
Despite the enthusiasm for expansion of TAVI indications to lower-
risk groups, it is possible that a number of patients fail to derive long-
term benefit in terms of survival and functional improvement. [12] 
The importance of careful patient selection can therefore not be 
overemphasised, both to be responsible in terms of resources and 
to ensure favourable patient outcomes and avoid futile procedures.
The difficulty in predicting risk in the TAVI community was 
identified in earlier attempts from the SOURCE (SAPIEN Aortic 
Bioprosthesis European Outcome) registry, where a satisfactory risk 
prediction model remained elusive despite analysis of comprehensive 
data on >1 000 patients undergoing TAVI.[8] The SOURCE registry 
contains procedural, 3-day and 1-year follow-up data for 1 038 
patients who had undergone TAVI at 32 European and African 
centres between November 2007 and January 2009. Multivariate 
analysis identified several factors that correlated with increased risk 
for 1-year mortality:
Transapical group. EuroSCORE, renal disease, liver disease, 
carotid artery stenosis >50% (in counterintuitive direction).
Transfemoral group. New York Heart Association (NYHA) class IV, 
renal disease, smoking, hypercholesterolaemia (in counterintuitive 
direction), and complete absence of any cardiovascular condition.
These multivariate analysis prognostic factors achieved a modest 
C-statistic of 0.65 for the transapical patients and 0.70 for the 
transfemoral patients. A C-statistic of ≤0.7 is of little or no clinical 
significance, and a C-statistic of 0.5 would be similar to a chance 
outcome. The research concluded that the factors identified as 
prognostic factors in the SOURCE registry data are likely to be of 
only limited value in developing a clinical prediction model.
The most important baseline predictors of poor outcome in the 
PARTNER trial were reduced exercise capacity, lower mean aortic 
valve gradients, oxygen-dependent chronic lung disease, chronic 
kidney disease and poor baseline cognition. Yet these factors yielded 
modest discrimination ability, with C-statistics of 0.66 and 0.64 in 
derivation and validation cohorts, respectively.[4]
Another attempt by Gilard et al.[13] using the FRANCE 2 cohort 
identified nine factors correlating with 30-day post-TAVI outcomes. 
Similarly, relatively disappointing C-statistics of 0.67 and 0.59 were 
seen in the derivation and validation cohorts, respectively.[13]
Table 6. Multivariate logistic regression analysis of identified univariate predictors for predicting 1-year survival*
Variable Level of effect Coefficient p-value OR 95% CI
Preprocedural BMI Favouring higher BMI 0.09 0.08 1.09 0.99 - 1.2
Preprocedural LVED Favouring smaller LVED –0.07 0.09 0.93 0.86 - 1.01
Preprocedural EF Favouring higher EF 0.01 0.69 1.01 0.97 - 1.05
Preprocedural AF n/a –0.5 0.11 0.37 0.11 - 1.23
Independent living n/a 0.16 0.69 1.38 0.29 - 6.7
Can drive a car n/a 0.78 0.02 4.74 1.27 - 17.66
Food acquisition: not by patient/spouse 
(external help)
n/a 0.24 0.55 0.62 0.13 - 2.9
OR = odds ratio; CI = confidence interval; BMI = body mass index; LVED = left ventricular end-diastolic diameter; EF = ejection fraction; AF = atrial fibrillation; n/a = not applicable.
*The level of the effect is also indicated by the coefficient. Multivariate analysis corrects for possible confounders among analysed variables. The OR CIs were calculated as per convention with a 
95% certainty interval. A certainty interval of 0.9 is felt to be clinically relevant, and if used, the CIs would not include 1 for BMI, LVED, AF and ability to drive a car.
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Fig. 1. ROC curve. Predictive value of seven identified factors (body mass 
index, left ventricular end-diastolic diameter, ejection fraction, atrial 
fibrillation, independent living, ability to drive car, method of food acquisition) 
for 1-year survival outcomes from discriminant analysis. With an ROC curve, 
an ideal risk prediction model would plot in the left upper corner of the graph 
(sensitivity 100% and specificity 100%). Posterior P (1) is the point along the 
curve that gives the best balance between sensitivity and specificity. (ROC = 
receiver operating characteristic; AUC = area under the curve.)
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The predictive ability and applicability of conventional risk models 
(EuroSCORE II and STS score), even in the surgical community, is 
a point of ongoing research owing to the changing risk profile of 
surgical patients, the marked improvement in surgical outcomes 
compared with the 1990s, and changes in surgical techniques. In 
a recent study evaluating the predictive ability of the STS score in 
surgical valve replacement, a C-statistic of 0.791 was found.[14] The 
STS score also possessed very modest predictive ability for 30-day 
TAVI mortality, with an area under the ROC curve of 0.674 (95% 
CI 0.541 - 0.807).[14]
Most recently, the role of cardiac biomarkers as possible predictors 
of unfavorable outcomes was assessed. The current understanding is 
that they may enrich current risk scores, but larger studies are still 
needed to clarify their role.[14] The most accurate outcome prediction 
model for TAVI candidates to date has come from the FRAILTY-AVR 
study. Afilalo et al.[15] propose the Essential Frailty Toolset (EFT) as the 
preferred frailty scale, with an AUC of 0.784 (95% CI 0.745 - 0.822). 
The components of the model are lower-extremity weakness, cognitive 
impairment, anaemia and hypoalbuminaemia. The model was also a 
predictor of worsening disability at 1 year. [15] The applicability of these 
scores remains unclear in the SA community (see Table 1 for results of 
previous prediction models in the TAVI community).
In our current work we have shown no correlation between 1-year 
survival and the majority of univariate factors assessed; notably, no 
outcome correlation was found for EuroSCORE, age, renal function 
and STS score. This echoes the peculiarity that intuitive factors do 
not necessarily predict outcome well. We present seven independent 
variables, which in our cohort attained a C-statistic of 0.8 in 
predicting 1-year survival. Although it is known that risk prediction 
models often over-perform in the cohorts they were derived from, 
and hence real-life predictive ability may be poorer, our work not 
only represents an improvement in the risk-predictive abilities of the 
factors identified by the SOURCE registry, but also outperforms the 
STS score in predicting risk. The first two parameters (EF and LVED) 
are continuous variables and showed a linear correlation with 1-year 
survival, so that smaller LVED and higher EF favoured survival. 
The other five parameters are categorical variables. Each parameter 
has a relative contribution/weight based on the coefficient during 
the multivariate logistic regression. Although AVA was associated 
with 1-year survival on univariate testing, it did not contribute 
significantly in the multivariate analysis and was omitted in the final 
model. We have omitted the final mathematical depiction of the 
model and chose only to publish the seven variables, as the model 
cannot be regarded as operational yet and needs to be prospectively 
validated on an external cohort of TAVI candidates.
Study limitations
The first limitation is that data collection stretched over a 7-year 
period during which there has been significant improvement in 
patient outcomes, attributable to growing expertise of the heart valve 
team and device development. Second, the research was subjected to 
the limitations of a retrospective design, with the investigators being 
limited in assessing factors that we collected during the implantation 
period. Third, although this is the largest published local cohort of 
TAVI patients, the sample size is still relatively small (e.g. compared 
with the SOURCE registry) and is subject to the limitations of a 
relatively small sample size. Finally, it must be stressed that the 
current work should not be regarded as a functional risk prediction 
model, but merely as the first step towards developing such a model 
that has withstood external validation.
Conclusions
We present the initial phases in the development of a TAVI risk 
prediction model derived from SA data. We postulate that the model 
will have greater applicability to the local community than models 
derived from international literature. The seven parameters, three 
of which are novel in TAVI literature, are tailored for the constraints 
of the SA medical community and show promising results in their 
combined capacity to predict 1-year survival. If the predictive ability 
of these variables survives the scrutiny of prospective external 
validation, they could prove to be a valuable asset in the assessments 
of TAVI patients in SA.
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